Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

ProMune Phase III lung cancer trial plans outlined in Coley's recent IPO prospectus filing. With licensee Pfizer funding ProMune for cancer applications, the bulk of the initial public offering proceeds will go toward expanding Coley's early-phase infectious disease program.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS062261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel